Transcatheter arterial embolization for cancer-related non-variceal upper gastrointestinal bleeding: A multicenter retrospective study of 107 patients - 01/02/23
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Highlights |
• | Transcatheter arterial embolization yields 99.1% technical success rate and 56.1% clinical success rate when used for the treatment of cancer-related non-variceal upper gastrointestinal bleeding. |
• | The 30-day all-cause and bleeding-related mortality rates are 17.8% and 13.1%, respectively after transcatheter arterial embolization for cancer-related non-variceal upper gastrointestinal bleeding. |
• | Transcatheter arterial embolization yields a major complication rate of 0.9% when used for the treatment of cancer-related non-variceal upper gastrointestinal bleeding:. |
Abstract |
Purpose |
The purpose of this study was to retrospectively evaluate the outcome of transcatheter arterial embolization (TAE) in the treatment of cancer-related non-variceal upper gastrointestinal bleeding (UGIB).
Materials and methods |
One-hundred and seven patients who underwent TAE for the treatment of cancer-related non-variceal UGIB at five institutions between June 2016 and May 2019 were retrospectively included. There were 78 men and 29 women, with a mean age of 60.6 ± 13.2 (SD) (age range: 31–87 years). Clinical success was defined as no rebleeding within 30 days after TAE. Rebleeding was defined as non-variceal UGIB resulting in a decrease in hemoglobin > 2 g/dL within 24 h. The Kaplan-Meier method was used to estimate actuarial probabilities of rebleeding and survival within 30 days after TAE. Univariable and multivariable analyses were performed to identify variables associated with clinical success and 30-day mortality.
Results |
Technical success was achieved in 106 out of 107 patients (99.1%). Positive angiographic findings (contrast extravasation and pseudoaneurysm) were observed in 30/107 patients (28.0%). Empiric embolization was performed in 77/107 patients (72.0%). Clinical success was achieved in 60/107 patients (56.1%). The 3-day, 7-day, and 30-day actuarial probabilities of rebleeding were 21.5%, 31.0%, and 44.6%, respectively. No variables were identified as predictors of clinical success. Nineteen patients (19/107; 17.8%) died within 30 days after TAE; of them, 14 (14/107; 13.1%) died due to bleeding-related causes. The 3-day, 7-day, and 30-day actuarial probabilities of survival were 91.6%, 88.8%, and 77.4%, respectively. A baseline hemoglobin level of ≤ 60 g/L (Odds ratio [OR]: 3.376; 95% confidence interval [CI]: 1.223–9.318; P = 0.019) and clinical failure (OR: 6.149; 95% CI: 2.113–17.893; P = 0.001) were identified as predictors of 30-day mortality. Major complications (gastrointestinal perforation) occurred in one patient (1/107; 0.9%). Minor complications (abdominal pain, fever, and vomiting) occurred in 19 patients (19/107; 17.8%).
Conclusion |
TAE is a safe treatment option for patients with cancer-related non-variceal UGIB, and seems to be effective in more than half of these patients.
Le texte complet de cet article est disponible en PDF.Index terms : Embolization, Gastric cancer, Gastrointestinal hemorrhage, Neoplasms, Therapeutic, Upper gastrointestinal bleeding
Abbreviations : CI, CT, CTA, GIB, NBCA, OR, PVA, SD, TAE, UGIB
Plan
Vol 104 - N° 2
P. 60-66 - février 2023 Retour au numéro
Article précédent
- Deep learning-based super-resolution gradient echo imaging of the pancreas: Improvement of image quality and reduction of acquisition time
- Maryanna Chaika, Saif Afat, Daniel Wessling, Carmen Afat, Dominik Nickel, Stephan Kannengiesser, Judith Herrmann, Haidara Almansour, Simon Männlin, Ahmed E. Othman, Sebastian Gassenmaier
- Discriminating between benign and malignant salivary gland tumors using diffusion-weighted imaging and intravoxel incoherent motion at 3 Tesla
- Rongli Zhang, Ann D. King, Lun M. Wong, Kunwar S. Bhatia, Sahrish Qamar, Frankie K.F. Mo, Alexander C. Vlantis, Qi Yong H. Ai
Bienvenue sur EM-consulte, la référence des professionnels de santé.